Date: 2012-10-09
Type of information: Grant
Company: AMP Therapeutics (Germany)
Investors: Federal Ministry of Education and Research (BMBF) (Germany)
Amount: € 1.8 million
Funding type: grant
Planned used: Proceeds from the financing will be used to advance AMPT’s Gram-negative antibiotic program. More specifically the pharmacological and toxicological profile of ATA peptides derived from insects will be defined in more detail to accelerate the development of AMPT’s product pipeline.
Others: AMP Therapeutics (AMPT), a company developing novel antibiotic therapies, has announced the successful acquisition of non-dilutive funding from Germany’ Federal Ministry for Education and Research (BMBF). In a joint application with Prof. Ralf Hoffmann’s group at the University of Leipzig the consortium was awarded a total grant volume of more than € 1.8 million. The funding will take the form of a non-repayable reimbursement of specific development costs expended by AMPT until September 2014. The total cost of this development program is estimated to be € 2.2 million of which the BMBF committed to provide up to € 1.8 millio in funding within its Innovative Therapies program.
Therapeutic area: Infectious diseases
